Versant Ventures

Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of novel therapies.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by Cimeio is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. The SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant. Its mission is to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Capsida is a biotechnology company focused on developing targeted gene therapies for monogenic and sporadic disorders affecting both the central nervous system and other areas of the body. The company utilizes a proprietary adeno-associated virus (AAV) engineering platform, which creates capsids specifically designed to target particular tissues and cells within affected organs. This advanced approach not only aims to enhance the efficacy of the therapies by ensuring they reach the intended sites of action, but also minimizes the impact on non-target tissues, thereby improving patient health outcomes in the treatment of life-threatening genetic disorders.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that focuses on drug discovery through its innovative platform targeting solute carrier (SLC) transporters. Established in 2016, the company aims to improve patient outcomes by developing small molecule therapies for various diseases, including those related to immunometabolism, lysosomal function, and mucosal defense. By utilizing advanced chemoproteomics techniques, Jnana accelerates the identification of therapeutic targets, addressing significant unmet medical needs in areas such as immuno-oncology, inflammatory disorders, and neurological diseases. The company's approach seeks to enhance drug discovery efficiency by comprehensively targeting the vast family of membrane proteins associated with SLC transporters.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

AAVLife is a gene therapy company based in Paris, France, founded in 2014. The company focuses on developing therapies for Friedreich's Ataxia Cardiomyopathy, a genetic disorder that leads to severe neurological and cardiac symptoms. AAVLife's innovative approach utilizes an adeno-associated virus to deliver a normal gene into cardiac tissue, which has shown promise in restoring cardiac function and reversing heart enlargement in preclinical models. The company has made significant progress in its research to determine optimal dosing and administration routes for upcoming clinical trials. AAVLife aims to engage with regulatory authorities to finalize the design of these trials, with plans to initiate an observational study and a Phase I/II clinical trial. Through its efforts, AAVLife is committed to advancing gene therapy solutions for patients affected by this life-threatening condition, emphasizing its dedication to patient communities and the organizations that support them.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Pathwork Diagnostics, located in Redwood City, California, specializes in developing and delivering innovative molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers, by utilizing genomic information from the tumors. Pathwork Diagnostics offers laboratory services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen tissues, providing essential support in cancer diagnosis and treatment planning.

Helicos BioSciences Corporation (Helicos) is a life sciences company, which has developed technology focused on the research, drug discovery and clinical diagnostics markets. Its True Single Molecule Sequencing (tSMS) technology enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid (RNA) (cDNA) and its approach of direct sequencing of RNA. Its Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA or RNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process and disposable supplies.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.

Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.